Omagine (OMAG) Stock Price, News & Analysis

Company Overview

Omagine, Inc. is a development‐stage medical technology company focused on the research, development and commercialization of advanced regenerative wound care products. The company’s proprietary platform is designed to deliver an in situ polymerizing hydrogel scaffold directly at the wound site, where it aims to mimic the body’s natural extracellular matrix and promote accelerated healing of both acute and chronic wounds.

Omagine’s lead product candidate, Regenerative Tissue Replacement (RTR), employs a bioactive formulation that conforms precisely to complex wound geometries and supports key biological processes such as cell migration, angiogenesis and tissue regeneration. The company is advancing RTR through preclinical development and preparing for potential clinical studies and regulatory filings to validate its safety and efficacy in challenging wound care indications.

Primarily serving the U.S. healthcare market, Omagine collaborates with academic research institutions, contract research organizations and clinical specialists to refine its wound care solutions and build a robust intellectual property portfolio. As a development‐stage entity, the company is positioning its technology for future commercialization, with the strategic goal of establishing a new standard of care for chronic wound management and other tissue repair applications.

Key Stats

• Today's Range: $0.0006 to $0.0006
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.04
• Volume: N/A
• Average Volume: 36,333 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Finance
• Industry: Real Estate Development
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:OMAG
• CIK: N/A
• Web: www.omagine.com
• Phone: +1-212-5634141
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A